IGF1R and renal cell carcinoma: IGF-1R-targeted therapy in RCC was implicated by an early finding of a greater than 10-fold reduction in tumor growth in mice bearing xenografts of human clear-cell RCC when administered with an antagonist to growth hormone-releasing hormone, which was attributed to a reduction of IGF-1 [11].